Global Trac Solutions, Inc. CEO, David Flores sits down to speak with Co-Founder & CEO, of Mydecine Innovations Group, Josh Bartch.
Similar Posts
The Spotlight Roundup-Can Psychedelics Help Brain Trauma?
July 21, 2021- This week’s Psychedelic Business News top stories…
Top 5 Catalysts for Psychedelic Stocks In The Second Half of 2021 (MNMD,CMPS,ATAI,TRYP, CYBN & MORE)
What are top 5 catalysts for psychedelic stocks in the second half of 2021? Stay tuned to hear how stocks like MindMed (NASDAQ: MNMD),
(NEO:MMED), Compass Pathways (NASDAQ: CMPS), atai Life Sciences ( NASDAQ: ATAI), Tryp Therapeutics, Cybin and more will affect the psychedelic industry in 2021.
Timestamps:
0:00 – Intro
1:38 – #5: A New Psychedelics ETF (PSIL)
4:57 – #4:California Decriminalizing possession of psychedelics, and Legalising the personal production of Psilocybin
7:30 – #3:The commencement of MANY phase 2a trials
10:16 – #2: MindMed’s Project Lucy phase 2b trial begins
11:47 – #1: Compass Pathways phase 2b trial results released
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Check out our website: thepsychedelicinvestor.com
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
#MindMed #MNMD #PsychedelicStocks
MindMed Stock Price Targets [How HIGH can $MMED / $MMEDF Go?]🚀
Today we are going to discuss my 5 year price targets for MindMed, MMEDF on the American OTC market, MMED on the Canadian Neo market and MMQ on the European Frankfurt Stock exchange.
Piggy backing off of a decades worth of positive research showing that substances like LSD, Ibogaine, psilocybin and MDMA can treat mental health illnesses better than current methods by an order of magnitude, MindMed is in my opinion by far the most advanced psychedelic medicines company that retail investors can buy on the public markets which is why MindMedicine is one of my top psychedelic stocks in 2021.
In this video, we’re going to look at 4 different 5 year price targets for MindMed, and assign them a level of probability. The four cases will be:
1. The 5 year bear case for MindMed’s stock
2. The Neutral case for MindMed LT
3. The bull case price target for MindMed
4. The Super Bull case
Timestamps:
0:00 – Intro
2:54 – The Bear Case for MindMed
5:37 – The Neutral Case/ MindMed’s Stagnation
7:49 – The Bull Case for MMED/MMEDF Stock
10:18 – The Super Bull Case for MindMed
13:08 – Note of Caution Plus Answer to Meor’s Nasdaq question
Just as a brief note, in this video we are going to be using MMEDF, and all figures will be in American dollars
And because this is all going to be speculation, the entirety of the episode will take place in, The Speculation Zone
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedStock #MMEDNews
Interview With Joshua Bartch
Mydecine Innovations Group’s Director, CEO & Co-Founder, Joshua Bartch chats with our Director of Content, Jill Ettinger.
Find Your Inner Healing with Psychedelic Therapy | ATMA CEO Interview
In today’s episode of PSYCBiz, James, the Psychedelic Investor, sits down with David Harder, Co-CEO of ATMA.
ATMA is a company that is primarily focused on training therapists on how to conduct psychedelic therapy.
The company also has plans to launch psilocybin clinical trials, treat depression patients in Canada under the SAP program, and work with Oregon in their legalization of psilocybin therapy.
This interview took place at the Catalyst Summit, a psychedelic conference that David Harder helped organize. This conference saw big names like Paul Stamets attend.
In the conversation, David and James get philosophical and discuss the nature of psychedelics and consciousness. Topics such as the right to try are also discussed.
To learn more about ATMA, visit: https://www.atmajourney.com/
To learn more about Catalyst, visit: https://catalystpresents.ca/
#psychedelics #therapy #magicmushrooms
Interview with Zoe Helene, Founder of Cosmic Sister
In our conversation, we discuss some of Zoe’s formative experiences in the creative arts which led her down the path of plant medicine advocacy, core feminist issues and how psychedelics play a role in furthering women’s movements, why an emphasis on equity and representation within the budding psychedelic industry is crucial and still has a long way to go, and so much more.